Any current/future new fundraising through debt or equity?

No explicit mention of new fundraising through debt or equity in the provided excerpts. Management emphasized "heads down execution" with no acquisitions unless the balance sheet improves, implying caution on new debt or equity raises. Debt reduction is a priority, aiming to reduce Net Debt to Rs. 2,600 crores by FY25 end and around Rs. 2,000 crores by FY26. Operating cash flow expected to fund capex and debt servicing, suggesting no immediate need for external fundraising. Capex for biotech expansion and site acquisition is planned within existing financial guidance (Rs. 200 crores o

Any current/future capex/capital investment/strategic investment?

Insulin manufacturing plant investment: Additional capex of Rs. 20-25 crores planned for the insulin piece at the acquired plant, included within the identified capex and not incremental. (Page 20) Biotech segment capex: Rs. 100-120 crores additional capex envisaged for various Biotech segments including Insulin, MABs, and Hormones, with Rs. 200 crores planned over FY25 and FY26 for Insulin, MABs, and Hormone manufacturing combined. (Pages 8, 19) Manufacturing lines: Plan to install six lines for Insulin (four for vials, two for cartridges), two lines for MABs, and additional hormone lines i

Future growth expectations in sales/revenue/volumes?

Domestic Branded Formulations (DBF) revenue targeted at Rs. 2,600 crores with 12-14% organic growth in FY25. Consolidated revenue expected to exceed Rs. 3,000 crores with an EBITDA margin of 35%. Biocon business forecasted to grow 27% in revenue with a margin expansion of approximately 1,000 bps. Swiss Parenterals aims for Rs. 330 crores revenue with 14% top-line growth and 30% EBITDA growth. Insulin franchise (including Basalog, Insugen, Xsulin, Xglar) anticipated to reach Rs. 340-350 crores, a 40% growth on the acquired base. Strong growth expected from super-specialty segments (Critical Car

Future growth expectations in earnings/operating earnings/profits/EPS?

**Base Business**: Expected organic revenue growth of 12-14% with an EBITDA margin of 37% in FY25. Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies. **Biocon Business**: Revenue growth of 27% with an EBITDA margin improvement of approximately 1000 basis points. Biocon-2 segment expected to achieve 28% EBITDA margin, a 900 bps improvement over acquisition base, with potential for mid to late-30s margins over 2-3 years. **Swiss Parenterals**: Projected revenue of Rs. 330 crores with a 35% EBITDA margin for the year. **Consolidated Outlook**: FY

Current/ Expected Orderbook/ Pending Orders?

Swiss Parenterals has an order book of nearly Rs. 130 crores for delivery in the current year. This is highlighted on Page 6, where the company mentions continuing to expand the product pipeline alongside this order book. No specific details are provided about order books or pending orders for other segments or the overall company beyond this figure.

ERIS Lifesciences LtdQ1 FY25Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,190P/E: 26.6Market Cap: ₹17.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Domestic Branded Formulations (DBF) revenue targeted at Rs. 2,600 crores with 12-14% organic growth in FY25.
Consolidated revenue expected to exceed Rs. 3,000 crores with an EBITDA margin of 35%.
Biocon business forecasted to grow 27% in revenue with a margin expansion of approximately 1,000 bps.
Swiss Parenterals aims for Rs. 330 crores revenue with 14% top-line growth and 30% EBITDA growth.
Insulin franchise (including Basalog, Insugen, Xsulin, Xglar) anticipated to reach Rs. 340-350 crores, a 40% growth on the acquired base.
Strong growth expected from super-specialty segments (Critical Care, Oncology, Nephrology) at 10%+ volume growth annually.
New product launches in Cardiology (Dapagliflozin plus Metoprolol and Dapagliflozin plus Bisoprolol) planned for Q2 to aid growth.
Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies.

Margin guidance

Category 3

Base Business: Expected organic revenue growth of 12-14% with an EBITDA margin of 37% in FY25. Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies.
Biocon Business: Revenue growth of 27% with an EBITDA margin improvement of approximately 1000 basis points. Biocon-2 segment expected to achieve 28% EBITDA margin, a 900 bps improvement over acquisition base, with potential for mid to late-30s margins over 2-3 years.
Swiss Parenterals: Projected revenue of Rs. 330 crores with a 35% EBITDA margin for the year.
Consolidated Outlook: FY25 revenue expected at Rs. 3,000+ crores with an EBITDA margin of 35%; consolidated margins may reach late 30s in future as manufacturing efficiency improves.
EPS/Profitability: Q1 showed 10% growth in cash EPS; overall profitability to improve with margin expansions and operational efficiencies.

See what ERIS Lifesciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of new fundraising through debt or equity in the provided excerpts.
Management emphasized "heads down execution" with no acquisitions unless the balance sheet improves, implying caution on new debt or equity raises.
Debt reduction is a priority, aiming to reduce Net Debt to Rs. 2,600 crores by FY25 end and around Rs. 2,000 crores by FY26.
Operating cash flow expected to fund capex and debt servicing, suggesting no immediate need for external fundraising.
Capex for biotech expansion and site acquisition is planned within existing financial guidance (Rs. 200 crores over FY25-26 for insulin, MAB, hormones).
Focus remains on rebuilding balance sheet strength rather than raising new funds at this time.

See what ERIS Lifesciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Insulin manufacturing plant investment: Additional capex of Rs. 20-25 crores planned for the insulin piece at the acquired plant, included within the identified capex and not incremental. (Page 20)
Biotech segment capex: Rs. 100-120 crores additional capex envisaged for various Biotech segments including Insulin, MABs, and Hormones, with Rs. 200 crores planned over FY25 and FY26 for Insulin, MABs, and Hormone manufacturing combined. (Pages 8, 19)
Manufacturing lines: Plan to install six lines for Insulin (four for vials, two for cartridges), two lines for MABs, and additional hormone lines in early stages. Capex will spill over 2-3 years. (Page 18)
Site acquisition cost: Rs. 105 crores spent on site acquisition as part of the overall capex. (Page 8)
Focused on building new biotech capabilities rather than maintenance capex. (Page 17)

Track ERIS Lifesciences Ltd — get its next earnings analysis in your feed

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisERIS Lifesciences Ltd

Rev 3Mar 3

See where ERIS Lifesciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does ERIS Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare ERIS Lifesciences Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What ERIS Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

ERIS Lifesciences Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does ERIS Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What ERIS Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season